Danaher

Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023

Retrieved on: 
Thursday, August 31, 2023
Research, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Abcam, Webcast, Danaher, Acquisition, EGM, Bookkeeping, Risk management

* Excludes the amortisation of the fair value of assets relating to the inventory acquired in connection with the acquisition of BioVision at June 30, 2022.

Key Points: 
  • * Excludes the amortisation of the fair value of assets relating to the inventory acquired in connection with the acquisition of BioVision at June 30, 2022.
  • ** Adjusted figures exclude system and process improvement costs, amortisation of fair value adjustments, strategic review costs, EGM costs, integration and reorganisation costs, amortisation of acquisition intangible assets and share-based payments.
  • “In the first half of 2023, we remained focused on supporting our global customers and meeting our business and corporate objectives.
  • Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community.

SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of September 15, 2023 in the Class Action Filed on Behalf of Danaher Corporation (DHR) Shareholders

Retrieved on: 
Thursday, August 31, 2023
Danaher Corporation, Telephone, COST, CLASS, COVID-19, Danaher, Growth, HOW, DHR, NYSE

NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Danaher Corporation (NYSE: DHR) alleging that the Company violated federal securities laws.

Key Points: 
  • NEW YORK, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Danaher Corporation (NYSE: DHR) alleging that the Company violated federal securities laws.
  • WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Danaher you have until September 15, 2023 to petition the court for lead plaintiff status.
  • Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
  • HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the DHR lawsuit, please contact J. Klein, Esq.

8 Key Trends in the $106 Billion Worldwide IVD Market

Retrieved on: 
Thursday, August 31, 2023
EUA, Mayo Clinic, Immunochemistry, Test management, Coronavirus, NGS, COVID-19, 2005 in television, Danaher, Fujifilm, Ford, Research, Mass spectrometry, Biomarker, Exact sciences, Eli Lilly, Sherlock, Amazon, Siemens Healthineers, Acquisition, Polymerase chain reaction, Roche, Medicine, OTC, IVD, Growth, AI, POC, FDA, PCR, Medical device, Renewable energy, Pharmaceutical industry, Vaccine, Pfizer

ARLINGTON, Va., Aug. 31, 2023 /PRNewswire/ -- In vitro diagnostics (IVDs) remain dynamic. The IVD market is a high R&D spend industry with constant innovations and routine interest from venture capital firms in diagnostic products.  Nevertheless, the past few years have been very disruptive for IVDs. However, the resilient IVD industry has weathered the pandemic and is forging ahead with new technologies and increased opportunities that will sustain market growth through the foreseeable future.

Key Points: 
  • The IVD market is a high R&D spend industry with constant innovations and routine interest from venture capital firms in diagnostic products.
  • The global IVD test market is estimated at $106 billion in 2023 and is expected to grow 3.8% annually through 2028.
  • This conclusion is among the analysis found in The Worldwide Market for In Vitro Diagnostic Tests, 16th Edition , the brand new market research report from leading firm Kalorama Information.
  • Beyond these developments, Kalorama Information emphasizes several other key trends that will shape the present and future of IVD testing.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Danaher Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 15, 2023 – (NYSE: DHR)

Retrieved on: 
Wednesday, August 30, 2023
Danaher Corporation, NEXT, COVID-19, Danaher, Growth, Fraud, DHR, Holding company, Security (finance)

NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Danaher Corporation.

Key Points: 
  • NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Danaher Corporation.
  • Shareholders who purchased shares of DHR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • DEADLINE: September 15, 2023 Shareholders should not delay in registering for this class action.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

DANAHER CORPORATION DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Danaher Corporation (NYSE: DHR)

Retrieved on: 
Tuesday, August 29, 2023
LLP, COVID-19, Danaher, DHR, Danaher Corporation, Projection, District court, Advertising, Complaint, Court, Growth, NYSE, News, Cryptocurrency, Security (finance), Tobacco, Pharmaceutical industry

Bernstein Liebhard LLP , a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Danaher Corporation (“Danaher” or the “Company”) (NYSE: DHR) between April 21, 2022 and April 24, 2023, inclusive (the “Class Period”).

Key Points: 
  • Bernstein Liebhard LLP , a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Danaher Corporation (“Danaher” or the “Company”) (NYSE: DHR) between April 21, 2022 and April 24, 2023, inclusive (the “Class Period”).
  • If you purchased or acquired Danaher securities, and/or would like to discuss your legal rights and options please visit Danaher Corporation Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] .
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Hersha Hospitality Trust (NYSE - HT), Thorne HealthTech, Inc. (Nasdaq - THRN), RPT Realty (NYSE - RPT), Abcam plc (Nasdaq - ABCM)

Retrieved on: 
Monday, August 28, 2023
Agreement, Tripura Merger Agreement, Brodsky, Kimco Realty, Danaher, KSL, DHR, Danaher Corporation, NYSE, KIM, Hersha Hospitality Trust, RPT Realty, KSL Capital Partners, RPT, Security (finance), Abcam

BALA CYNWYD, Pa., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.

Key Points: 
  • BALA CYNWYD, Pa., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations.
  • If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
  • Under the terms of the Agreement, Thorne will be acquired by L Catterton for $10.20 per share in cash for each share of Thorne.
  • Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits.

Danaher to acquire Abcam for $24.00 per Share

Retrieved on: 
Monday, August 28, 2023
Professional Services, Health, Other Health, Finance, Research, Science, Biotechnology, Morgan Stanley, Lord Chief Justice of England and Wales, Danaher, High court, DHR, Biomarker, England, Antibody, Danaher Corporation, Acquisition, Lazard, Latham & Watkins, Transaction, Drug discovery, Hand, NYSE, Pharmaceutical industry, Cryptocurrency, Management, Abcam

Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher’) will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).

Key Points: 
  • Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher’) will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).
  • The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors.
  • Alan Hirzel, Chief Executive Officer of Abcam, said: “Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community.
  • Danaher expects to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.

ABCM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Abcam plc Is Fair to Shareholders

Retrieved on: 
Monday, August 28, 2023
Class Action Lawsuit, Professional Services, Legal, Danaher Corporation, Danaher, Fraud, Advertising, Sale, Security (finance), Abcam

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Abcam plc (NASDAQ: ABCM) to Danaher Corporation for $24.00 per share in cash is fair to Abcam shareholders.

Key Points: 
  • Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Abcam plc (NASDAQ: ABCM) to Danaher Corporation for $24.00 per share in cash is fair to Abcam shareholders.
  • On behalf of Abcam shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.
  • Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Danaher to Acquire Abcam

Retrieved on: 
Monday, August 28, 2023
Danaher, DHR, Research, Biomarker, Antibody, Danaher Corporation, The Company, Acquisition, Drug discovery, Hand, NYSE, Fine chemical, Management, Abcam

WASHINGTON, Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash.

Key Points: 
  • WASHINGTON, Aug. 28, 2023 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or the "Company"), a global science and technology innovator, announced today that it has entered into a definitive agreement to acquire Abcam plc (NASDAQ: ABCM), a leading global supplier of protein consumables, pursuant to which Danaher will acquire all of the outstanding shares of Abcam for $24.00 per share in cash, or a total enterprise value of approximately $5.7 billion including assumed indebtedness and net of acquired cash.
  • Rainer M. Blair, President and Chief Executive Officer, Danaher, said: "We couldn't be more excited to have Abcam join Danaher.
  • Alan Hirzel, Chief Executive Officer, Abcam, said: "Our strategy has transformed Abcam to become a scale innovator and important catalyst in the global life science community.
  • Danaher expects to fund the acquisition using cash on hand and proceeds from the issuance of commercial paper.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Danaher Corporation of Class Action Lawsuit and Upcoming Deadline – DHR

Retrieved on: 
Saturday, August 26, 2023
Vaccine, LLP, Biotechnology, COVID-19, Danaher, DHR, Research, Person, Danaher Corporation, Projection, Ext, SEC Rule 10b-5, District court, Action Replay, Complaint, Cepheid variable, Biophysical environment, Court, Growth, Pomerantz, NYSE, News, Pharmaceutical industry, Diagnosis

NEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Danaher Corporation (“Danaher” or the “Company”) (NYSE: DHR), and certain officers.

Key Points: 
  • NEW YORK, Aug. 26, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Danaher Corporation (“Danaher” or the “Company”) (NYSE: DHR), and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.